Eli Lilly CEO outlines company priorities

09/25/2008 | Google

Eli Lilly and Co. will focus on developing biotech drugs for personalized treatment and expanding networks with other firms to accelerate drug development as the company faces patent expiration for its best-selling medicines, CEO John Lechleiter said in a speech. Lilly is also planning more job cuts and will not be seeking large-scale mergers or acquisitions, Lechleiter said.

View Full Article in:

Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ